Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by palinc2000on Feb 26, 2024 5:56pm
115 Views
Post# 35900227

RE:RE:RE:RE:RE:RE:RE:RE:Wonder what edt’s FORTUNE COOKIE

RE:RE:RE:RE:RE:RE:RE:RE:Wonder what edt’s FORTUNE COOKIE

Where did you see that Baxter will be getting "" half" of the revenues?

BlueJays9293 wrote: Sometimes it's crazy to me what people waste their time thinking/talking about.  I've seen Spectral switch between CAD and USD all within the same Sedar filing.  Talk about missing the forest for the trees.  Then lately I see all this complaing about the size of the distribution agreement milestone payments.  Well to these people I ask, how many tens of millions do you think Baxter is going to have to spend in marketing and commercialization in year #1 & #2 of PMX authorization????  50mm?  75mm?  100mm?  Even with FDA approval it costs a ton of money getting the word out, convincing doctors/hospitals/insurance companies and ultimately driving PMX to become the SOC as quickly as possible.

Go look at Spectral's slide # 16 again and you will see that after Baxter pays these expenses, their half of PMX revenue won't even cover these cost at a 15% penetration.  Spectral has Zero cost/expenses commercializing PMX, that huge burden is completely on Baxter.  Our revenue/earnings off of PMX is a pure as possible.  

 

<< Previous
Bullboard Posts
Next >>